Skip to main content

Market Overview

Radiopharmaceuticals Market ($13.81Bn by 2028) Growth Forecast at 9% CAGR During (2021-2028) - COVID-19 Impact and Global Analysis by


New York, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Radiopharmaceuticals Market: Key Insights
According to our new research study on "Radiopharmaceuticals Market to 2028 – Global Analysis and Forecast – by Type, Product Type, Application, and End User," the Radiopharmaceuticals Market is projected to reach US$ 13,818.17 million by 2028 from US$ 7,550.74 million in 2021; it is expected to grow at a CAGR of 9.0% during 2021–2028.

Radiopharmaceuticals Market: Competitive Landscape and Key Developments
Cardinal Health, GE Healthcare, Curium, Lantheus Medical Imaging, Bayer AG, Bracco Imaging, Eczacýbaþý-Monrol Nuclear Products, Nordion, Advanced Accelerator Applications, and NTP Radioisotopes are among key companies operating in the radiopharmaceuticals market. Leading players are focusing on the new product launch, expansion and diversification of their market presence, and acquisition of new customer base, thereby tapping prevailing business opportunities.

In July 2021, Lantheus received the US FDA approval for PYLARIFY (piflufolastat F 18) injection, a first and only commercially available PSMA PET imaging agent for prostate cancer. PYLARIFY was developed to target PSMA, a protein that is overexpressed on the surface of more than 90% of primary and metastatic prostate cancer cells.

Get Exclusive Sample Pages of Radiopharmaceuticals Market - COVID-19 Impact and Global Analysis with Strategic Insights at

In June 2021, Curium successfully completed the acquisition of the Austrian radiopharmaceuticals Company IASON, further expanding its footprint in Europe for its broad portfolio of life saving diagnostic solutions.

In June 2021, Bayer AG announced the acquisition of Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc. Through this acquisition, Bayer AG will obtain exclusive rights to a differentiated alpha radionuclide investigational compound based on actinium-225 and a small molecule directed toward prostate-specific membrane antigen (PSMA).

In 2020, North America dominated the global radiopharmaceuticals market. The market growth in the region is attributed to the prevalence of chronic disorders and the presence of supportive government plans for the development of research regarding radiopharmaceuticals. As per the Alzheimer's Association, in 2019, approx. 5.8 million Americans were suffering from Alzheimer's and the number is expected to rise to approx. 14 million by 2050. In addition, the introduction of innovative products is driving the market growth. For instance, in January 2021, Actinium Pharmaceuticals, Inc. collaborated with Astellas Pharma Inc. to develop novel targeted radiotherapies using its Antibody Warhead Enabling (AWE) technology platform.

The COVID-19 pandemic affected health care services from interrupting the regular patient flow to health care facilities, stressing, and overwhelming the health care resources. The COVID-19 pandemic has disrupted the spectrum of cancer care, including delaying diagnosis and treatment, and halting clinical trials in the region. More than 2 million people are diagnosed with cancer annually in Southeast Asia. The COVID-19 is having a detrimental effect on cancer patients worldwide, and negatively impacting the growth of the radiopharmaceuticals market.

Download Sample PDF Brochure of Radiopharmaceuticals Market Growth Research Report at

Based on type, the radiopharmaceuticals market is bifurcated into diagnostic nuclear medicine and therapeutic nuclear medicine. The diagnostic nuclear medicine segment is holding a larger share of the market and is anticipated to register a higher CAGR during 2021–2028. By product type, the market is segmented into Technetium-99m, Thallium-201, Gallium-67, Iodine-131, Copper-64, and other. The Technetium-99m segment is holding the largest share of the market, whereas the gallium-67segment is anticipated to register the highest CAGR during the forecast period. By application, the market is segmented into oncology, cardiology, neurology, and others. The oncology segment is holding the largest market share in 2021. However, the cardiology segment is estimated to register the highest CAGR during the forecast period. By end user, the market is segmented into hospitals, imaging centers, academic and research centers, and others. The hospitals segment is holding the largest market share. However, the imaging centers segment is estimated to register the highest CAGR during the forecast period.

The use of nuclear medicine procedures is expanding rapidly, as PET and SPECT continue to improve the accuracy of detection, localization, and characterization of a disease. PET and SPECT are among the nuclear medicine radiology modalities employed in clinical settings. As per the Society of Nuclear Medicine, every year, ~20 million nuclear medicine procedures are performed with radiopharmaceuticals and imaging instruments to diagnose disease and deliver targeted treatment in the US. These techniques have also been adopted in various fields, such as immunology, infection, gastroenterology, cardiology, oncology, neurology, and psychiatry, for diagnosis and other applications. Advanced nuclear medicines and modern imaging equipment are assisting doctors in diagnosing diseases in a better manner and in less time. Continuous development of new radiopharmaceuticals for the PET/CT and SPECT/CT platforms, which are used in novel clinical applications such as neurology and orthopedics, along with the increasing accuracy of different tumor staging methods, are further contributing to the market growth.

Order a Copy of Radiopharmaceuticals Market Shares, Strategies and Forecasts 2021-2028 Research Report at

Radiopharmaceuticals Market: Segmental Overview
In terms of application, the cardiology segment is anticipated to register the highest CAGR in the radiopharmaceuticals market during the forecast period. The market growth for the segment is attributed to the increasing adoption of nuclear medicine in diagnosing and treating heart disease.

Browse Related Reports:
Nuclear Medicine Equipment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Single Photon-Emission Computed Tomography (SPECT), Planar Scintigraphy, and Positron Emission Tomography (PET)); Application (Oncology, Cardiology, Neurology, and Other Applications); End User (Hospitals, Imaging Centers, and Academic and Research Centers), and Geography -

Nuclear Medicine Imaging Equipment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Single-Photon Emission Computed Tomography, Positron Emission Tomography); Application (Neurology, Oncology, Cardiology, Others); End User (Hospitals, Imaging Centers, Academic and Research Institutes) and Geography -

Prostate Cancer Nuclear Medicine Diagnostics Market Forecast to 2028 - Covid-19 Impact and Global Analysis - by Type (SPECT, PET); PET Product (F-18, C11, GA 68 PSMA), and Geography -

PET Nuclear Medicine Market Forecast to 2028 - COVID-19 Impact and Global Analysis By : Type ( F-18, Rb-82, Other PET Isotopes ); Applications ( Oncology, Cardiology, Neurology, Other PET Applications ) -

SPECT Nuclear Medicine Market Forecast to 2028 - COVID-19 Impact and Global Analysis By : Type ( TC-99m, I-123, Tl-201, GA-67, Other SPECT Isotopes ); Application ( Cardiology, Bone Scans, Thyroid Applications, Pulmonary Scans, Other SPECT Applications ) -

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Press Release -

Connect With Us on:
RSS/Feeds: |

Primary Logo

View Comments and Join the Discussion!

Latest Ratings

FTCICredit SuisseMaintains10.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at